deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 6-arm NCT03233139

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Cemiplimab (Anti-PD-1) and Other Agents in Japanese Patients With Advanced Malignancies

Sponsor: Regeneron Pharmaceuticals

Conditions Advanced Malignancies
Interventions Cemiplimab Fianlimab Gemcitabine Ipilimumab Paclitaxel Pemetrexed Platinum-doublet chemotherapy
Updated 20 times since 2017 Last updated: Feb 9, 2026 Started: Jun 21, 2017 Primary completion: Sep 30, 2027 Completion: Sep 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Malignancies and is currently ongoing. Regeneron Pharmaceuticals leads this study, which shows 20 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2017 – ~Feb 2018 · 6 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Jul 2019 · 5 months · monthly snapshot~Jul 2019 – ~May 2020 · 10 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~May 2025 · 3 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 4 months · monthly snapshot

Change History

20 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1

  3. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Feb 2025 — May 2025 [monthly]

    Recruiting PHASE1

  5. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE1

▶ Show 15 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  2. Dec 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

  3. Oct 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  4. Sep 2022 — Oct 2023 [monthly]

    Recruiting PHASE1

  5. Feb 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  6. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE1

  7. Jan 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  8. May 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  9. Jul 2019 — May 2020 [monthly]

    Recruiting PHASE1

  10. Feb 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  11. Oct 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  12. Jul 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  13. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  14. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  15. Aug 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Regeneron Pharmaceuticals
Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chuo Ku, Japan , Hirakata, Japan , Hiroshima, Japan , Kanazawa, Japan , Kobe, Japan , Kurashiki, Japan , Kurume, Japan , Nagasaki, Japan , Nagoya, Japan , Osaka, Japan and 8 more locations